QQ客服 官方微博 反馈留言

	A phase I dose escalation study of BGB-290 in Chinese subjects with advanced ovarian, fallopian, and primary peritoneal, or advanced triple-negative breast cancer
	Xu, Binghe; Yin, Yongmei; Song, Yan; Li, Wei; Huang, Xiang; Brachmann, Rainer; Tang, Tristin; Yang, Haiyuan; Ge, Ruimin; Mu, Song
	2018
卷号	78期号:13
ISSN号	0008-5472
DOI	10.1158/1538-7445.AM2018-CT050
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6347109
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Xu, Binghe,Yin, Yongmei,Song, Yan,et al. A phase I dose escalation study of BGB-290 in Chinese subjects with advanced ovarian, fallopian, and primary peritoneal, or advanced triple-negative breast cancer[J],2018,78(13).
APA	Xu, Binghe.,Yin, Yongmei.,Song, Yan.,Li, Wei.,Huang, Xiang.,...&Dong, Mei.(2018).A phase I dose escalation study of BGB-290 in Chinese subjects with advanced ovarian, fallopian, and primary peritoneal, or advanced triple-negative breast cancer.,78(13).
MLA	Xu, Binghe,et al."A phase I dose escalation study of BGB-290 in Chinese subjects with advanced ovarian, fallopian, and primary peritoneal, or advanced triple-negative breast cancer".78.13(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。